ISSN 1866-8836
Клеточная терапия и трансплантация

Изменить отображение страницы на: только анонсы

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Cellular factors of antitumor immunity in patients with chronic lympholeukemia
Г. Зайцева, Наталья Исаева, Тамара Загоскина
Clinical and pathological characterization of the t(14;19)(q32;q13)-positive splenic marginal zone lymphoma
Hunan Julhakyan, Татьяна Обухова, Ирина Капланская, Римма Самойлова, Андрей Воробьев
Expression of tumor-associated genes in multiple myeloma patients during high-dose chemotherapy and auto-SCT
Елена Паровичникова, Валерий Савченко, Татьяна Гапонова, Лидия Менделеева, Андрей Мисурин, Елена Варламова
Prognostic value of apoptosis of tumor clone bone marrow cells in patients with multiple myeloma
Станислав Бессмельцев, Л. Бубнова , Жанна Чубукина
Treatment results of children with Hodgkin’s disease (HD) according to protocols DAL-HD and GPOH-HD
Маргарита Белогурова, Галина Радулеску, Эмилия Чавпецова, Людмила Шац, Татьяна Викторович, Юлия Диникина
Salvage therapy in relapsed Hodgkin's lymphoma patients
Александр Попа, Георгий Менткевич, Елена Беляева, Ольга Морозова, Андрей Слугин
Anemias in lymphomas: pathogenesis mechanisms
Анна Лямкина, Татьяна Поспелова
Impact of positron emission tomography on primary staging and changing the therapeutic modality in lymphoma patients
Борис Афанасьев, Наталья Михайлова, Марина Тлостанова, Юлия Виноградова, Екатерина Иванова, Анна Критская, Сергей Королев, Анна Рац, Александр Пугачев, Николай Ильин, Леонид Тютин
High-dose melphalan versus melphalan plus dexamethasone in patients with AL amyloidosis
Аксель Цандер, Борис Афанасьев, Анна Смирнова, Алексей Смирнов
Allogeneic stem cell transplantation in multiple myeloma: single centre experience of 112 patients
Тапани Рууту, Liisa Volin, Heli Uotinen, Eeva Juvonen, Anne Nihtinen
The role of p53 polymorphisms in non–Hodgkin’s lymphomas’ susceptibility and prognosis
Татьяна Поспелова, Елена Воропаева, Михаил Воевода, Ольга Бересина
Effects of targeted therapy of multiple myeloma according to the City Hematological Center of Novosibirsk
Татьяна Поспелова, Наталья Скворцова, София Ковальчук
Association between HLA class I antigens and survival length in patients with multiple myeloma
Г. Зайцева, Тамара Загоскина, Елена Сенькина, Константин Мартынов
Bone marrow angiogenesis is a prognostic value in patients with multiple myeloma undergoing high-dose therapy and autologous stem cell transplantation
Елена Паровичникова, Валерий Савченко, Лидия Менделеева, Елена Варламова, Ирина Капланская, Ольга Покровская, Сергей Куликов
Virus participation in renal damage in AL patients: histopathological study
Елена Паровичникова, Валерий Савченко, Ирина Капланская, Екатерина Ворожейкина, Владимир Варшавский, Екатерина Голицына, Евгения Гласко, Людмила Бирюкова

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Cellular factors of antitumor immunity in patients with chronic lympholeukemia

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Clinical and pathological characterization of the t(14;19)(q32;q13)-positive splenic marginal zone lymphoma

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Cases of secondary acute myeloid leukemia and myelodysplastic syndrome in patients with multiple myeloma

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Expression of tumor-associated genes in multiple myeloma patients during high-dose chemotherapy and auto-SCT

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Prognostic value of apoptosis of tumor clone bone marrow cells in patients with multiple myeloma

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Treatment results of children with Hodgkin’s disease (HD) according to protocols DAL-HD and GPOH-HD

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Salvage therapy in relapsed Hodgkin's lymphoma patients

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Supporting therapy of natural zeolites at patients with lymphoproliferative diseases

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Anemias in lymphomas: pathogenesis mechanisms

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Impact of positron emission tomography on primary staging and changing the therapeutic modality in lymphoma patients

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

High-dose melphalan versus melphalan plus dexamethasone in patients with AL amyloidosis

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Allogeneic stem cell transplantation in multiple myeloma: single centre experience of 112 patients

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

The role of p53 polymorphisms in non–Hodgkin’s lymphomas’ susceptibility and prognosis

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Effects of targeted therapy of multiple myeloma according to the City Hematological Center of Novosibirsk

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Association between HLA class I antigens and survival length in patients with multiple myeloma

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Genetic polymorphisms of CYP1A1, GSTM1, GSTT1, and GSTP1 genes in В-cellular chronic lymphocytic leukemia (B-CLL)

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Unusual B-cell lymphoproliferative disorders and the new WHO classification

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Bone marrow angiogenesis is a prognostic value in patients with multiple myeloma undergoing high-dose therapy and autologous stem cell transplantation

F. Lymphoproliferated diseases (Lymphoma, Myeloma)

Virus participation in renal damage in AL patients: histopathological study